Physician profile
Joseph Glick
NPI 1346437506
$6,847.25
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $1,289 · 2021: $1,787 · 2022: $1,436 · 2023: $1,072 · 2024: $58.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,089.25 | 2021-2023 | |
| Amgen INC. | $727.95 | 2019-2023 | Aimovig |
| Novo Nordisk INC | $620.47 | 2019-2023 | Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $565.47 | 2019-2023 | Fasenra, Farxiga |
| Glaxosmithkline, LLC. | $461.02 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $355.25 | 2019-2024 | Mounjaro, Reyvow, Emgality |
| Pfizer INC. | $287.44 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $194.87 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.35 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.98 | 2019-2022 | |
| Allergan, INC. | $180.94 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.29 | 2019-2023 | Ofev, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $148.78 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $135.20 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $129.34 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Glick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.